Sino Biopharm says FDA clears IND for TQB6426 GPC3 ADC trial in advanced tumors

PUBT · 1d ago
Sino Biopharm says FDA clears IND for TQB6426 GPC3 ADC trial in advanced tumors
  • FDA granted IND clearance for TQB6426, a GPC3-targeting antibody-drug conjugate from Sino Biopharmaceutical’s Chia Tai Tianqing unit.
  • Phase I trial to start for advanced malignant tumors, assessing safety, tolerability, pharmacokinetics, preliminary efficacy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260903-12319494), on September 03, 2026, and is solely responsible for the information contained therein.